ArticleJournal of clinical hypertension (Greenwich, Conn.)2026
Fixed-Dose Combinations for Hypertension: Barriers to Use and Opportunities for Health Systems.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUncontrolled hypertension is a leading driver of heart disease, chronic kidney disease, heart failure, dementia, stroke, and pregnancy-related complications. Fixed-dose combinations (FDCs) are guideline-endorsed first-line therapies that improve blood pressure control by reducing pill burden, improving adherence, and targeting multiple pathophysiological mechanisms. However, FDC utilization remains low across U.S. health systems. Few studies examine the factors influencing FDC uptake; existing qualitative studies rarely interrogate structural barriers or formulate stakeholder-informed recommendations.
methodsWe explored the perspectives of providers, population health stakeholders, and health system executives through semi-structured interviews/thematic analysis to identify structural and provider-level barriers to FDC utilization and formulate recommendations for health systems.
resultsStructural barriers included low exposure to FDCs early in training, entrenched monotherapy-reliant cultures, workflow constraints, fragmented formularies, and absent performance incentives and leadership endorsements. Provider-level perspectives and practices diverged: clinicians reported minimal use of FDCs, limited familiarity with FDCs, and concerns about dosage inflexibility and adverse effects. By contrast, pharmacists and nurse practitioners identified as major proponents of FDCs, demonstrated broad familiarity with therapeutic and cost advantages, and reframed clinicians concerns as misconceptions due to limited exposure.
conclusionsTo improve FDC utilization, we propose: (1) integrating FDC exposure into early medical and pharmacy curricula; (2) embedding decision-support tools and SmartSets that prompt FDC consideration into electronic medical records; (3) expanding team-based care models to distribute responsibility for medication intensification; (4) securing leadership endorsements, novel incentive structures for providers, and data tracking mechanisms; and (5) fostering normative change through champions, CME-accredited workshops, and socialization strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.